Is venetoclax effective for multiple myeloma? Can it be cured?

Venetoclax has a certain therapeutic effect on multiple myeloma, but whether it can be completely cured varies from person to person.

Venetoclax is a highly selective oral BCL-2 inhibitor. In multiple myeloma, the bone marrow microenvironment induces increased expression of anti-apoptotic BCL-2 family proteins, thereby promoting the survival of multiple myeloma cells. Venetoclax can induce apoptosis in multiple myeloma cells, thereby achieving therapeutic effects.

According to clinical studies such as theBELLINI trial, the treatment regimen of venetoclax plus bortezomib and dexamethasone can significantly extend the progression-free survival of patients with relapsed or refractory multiple myeloma. For example, at a median follow-up of 18.7 months, the median progression-free survival in the venetoclax group was 22.4 months, compared with 11.5 months in the control group. These data confirm the effectiveness of venetoclax in the treatment of multiple myeloma.

However, it is important to note that each patient's specific situation and response is different. Although venetoclax can prolong progression-free survival, not all patients can achieve complete cure. In addition, some side effects may occur during treatment, such as an increased risk of infection, which will also affect the treatment effect and the patient's quality of life.

Multiple myeloma is a complex disease, and treatment with a single drug often fails to achieve optimal results. Therefore, while using venetoclax, doctors usually formulate a comprehensive treatment plan based on the patient's specific situation, including the combination of chemotherapy, radiotherapy, immunotherapy and other methods.